-The Economic Times Should drug companies make clinical trials data public? All over the world, drug regulators are increasingly in favour of doing so, much to the discomfort of pharmaceutical companies, and the London-based European Medicines Agency (EMA) is the first mover in this regard. As the journal Nature reports, EMA is likely to do so by next year, at least for some clinical trials data. On April 19, all the...

-The Hindu The Justice Verma Committee report acts as a blueprint for the radical transformation of gender relations within the framework of constitutional guarantees and gender equality. However, the adoption of the Criminal Law Amendment Act 2013 by Parliament on March 19, 2013, does not go beyond legal change. Prof. Hasan argues that if political parties are serious about the rights of women, the Women's Representation Bill must be passed...

-The Business Standard Court denies Swiss drug firm patent protection for its anti-cancer drug Glivec; domestic industry hails verdict The Supreme Court on Monday dismissed Novartis AG's appeal for patent protection of its anti-cancer drug, Glivec, putting an end to a seven-year battle between the Swiss drug maker, several domestic generic manufacturers, as well as patient groups fighting for affordable medicines. A Bench of judges Aftab Alam and Ranjana Desai said in a...

-The Times of India The Supreme Court on Monday rejected pharma giant Novartis AG's plea to preserve its patent over a life-saving cancer drug, Glivec, drawing a huge sigh of relief from thousands of patients in India and in dozens of developing countries as the fear of an almost 15-fold escalation of drug costs receded. It is the biggest setback for multinational pharma companies, which have been denied patent protection...

-The Times of India MUMBAI: Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics of the nearly Rs 70,000 crore Indian pharma market. Triggering a full-blown patent fight with US-based Merck, domestic generic company Glenmark has launched a more affordable version of the multinational's blockbuster...